Abstract 299P
Background
With the increasing proportion of women surviving carcinoma cervix, quality of life becomes an important issue. Most of the diagnosed women belong to the sexually active group (mean age 50 years). Therefore impact on sexual health is vital. Since there are only few studies on the topic, this study is to assess sexual dysfunction issues in patients treated with multimodality therapy using the LENT SOMA scores.
Methods
The study was prospective. A total of 85 patients were accrued comprising 6 stage IB, 6 stage II A, 25 stage II B, 2 stage IIIA, 45 stage III B and 1 stage IV A disease. Sixty six patients were treated with radiotherapy in which 46 patients received chemoradiotherapy and 19 had surgery prior to postoperative radiotherapy. The mean age was 47.81 years with a range of 2568 years. Completion of LENT SOMA scale and Statistical analysis for sexual dysfunction scores was done- stage wise and treatment wise.
Results
Mean subjective sexual function and satisfaction scores was highest in stage IIIA disease (0.0972) while maximum subjective sexual score was seen in stage IIB disease (0.94). Mean objective score VG (Vagina) was highest in stage IVA and maximum score (0.80) was seen in stage IIIB. The mean subjective sexual function and satisfaction score was highest (0.4601) in patients in which gap between treatment and interview was 11 years and maximum score was highest (0.94) in same group. The mean subjective sexual function and satisfaction score was highest (0.4601) in patients who were treated in earlier years when compared with other patients p value-0.093). Sexual function and satisfaction maximum score was highest in combined surgery and radiotherapy group (0.94) and minimum in RT alone group (0.54). The objective mean score VG (Vagina) was highest in combined surgery and radiotherapy group and maximum score(0.80) was highest in the radiotherapy(+chemo) group.
Conclusions
Currently there is no single self-report measure in routine clinical follow use which is easy to complete and incorporates all aspects of sexual health for people affected by cancer. We used LENT SOMA scale in our study, it provides a comprehensive system to assess treatment induced sexual difficulties to score the impact of radiotherapy morbidity in cervical cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
341P - NUP214 gene rearrangements in leukemia patients: Case series from a single institution
Presenter: Yu Jeong Choi
Session: Poster Display
Resources:
Abstract
344P - Venetoclax and azacitidine compared with azacitidine monotherapy for acute myeloid leukemia patients: A systematic review and meta-analysis
Presenter: Azzahra Noersamsjah
Session: Poster Display
Resources:
Abstract
345P - Safety and efficacy of platinum substitution in induction chemotherapy for mantle cell lymphoma
Presenter: Omali Pitiyarachchi
Session: Poster Display
Resources:
Abstract
346P - An assessment of marrow-infiltrating T cells in early relapsed hematologic cancer patients after allogeneic hematopoietic stem cell transplantation
Presenter: Ik-Chan Song
Session: Poster Display
Resources:
Abstract
347P - New targets for adult T cell leukemia/lymphoma (ATLL): A map for ATLL immunotherapy
Presenter: Zahra Rezaei Borojerdi
Session: Poster Display
Resources:
Abstract
348P - In-depth molecular analysis in the diagnosis of lymphomas with lymphoplasmacytic differentiation may provide a more precise diagnosis and rational treatment allocation
Presenter: Ella Willenbacher
Session: Poster Display
Resources:
Abstract
349P - Overall survival and progression-free survival comparison of lenalidomide + standard therapy versus standard therapy only in indolent lymphoma: A meta-analysis
Presenter: Kevin Winston
Session: Poster Display
Resources:
Abstract
350P - Intratumoural CD66b+ to predict treatment response in diffuse large B cell lymphoma (DLBCL)
Presenter: Mita Adriani
Session: Poster Display
Resources:
Abstract
351P - Clinical features and treatment outcomes of Waldenstrom macroglobulinemia patients: A single center study
Presenter: Devi Amelia
Session: Poster Display
Resources:
Abstract
352TiP - Randomized phase III study of daratumumab (D) versus bortezomib plus D as a maintenance therapy after D-MPB for elderly or non-elderly patients refusing transplant with untreated multiple myeloma (JCOG1911, B-DASH study)
Presenter: Tomotaka Suzuki
Session: Poster Display
Resources:
Abstract